An intermittent schedule, in a colorectal cancer mice model, ceralasertib 7 days on, 7 days off, combined with the anti-PD-L1 antibody durvalumab, significantly improved survival through a CD8+ T-cell-dependent mechanism. Here, CD274 is linked to colorectal cancer.